XV
X-VAX is developing mucosal vaccines targeting pathogens like herpes, utilizing advanced adjuvant formulations to enhance immune response at mucosal surfaces. This approach aims to provide effective protection against infections that enter the body through mucosal membranes, addressing a significant gap in current vaccine offerings.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- X-VAX is developing mucosal vaccines targeting pathogens like herpes, utilizing advanced adjuvant formulations to enhance immune response at mucosal surfaces. This approach aims to provide effective protection against infections that enter the body through mucosal membranes, addressing a significant gap in current vaccine offerings.